The urethral stricture treatment devices market size has grown strongly in recent years. It will grow from $1.47 billion in 2025 to $1.59 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to rise in urological disorders, aging male population, catheterization procedures growth, hospital urology department expansion, surgical stricture treatments.
The urethral stricture treatment devices market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growth in minimally invasive urology, demand for long-term stent solutions, advanced biomaterial adoption, outpatient procedure expansion, personalized urology devices. Major trends in the forecast period include minimally invasive stricture management, balloon dilation technologies, advanced urethral stents, improved catheter materials, outpatient urology procedures.
The growing incidence of benign prostatic hyperplasia (BPH) and neurogenic bladder is expected to drive the growth of the urethral stricture treatment devices market. BPH is a common condition among older men, characterized by an enlarged prostate that can obstruct urinary flow and heighten the risk of urethral strictures. The rise in BPH cases is largely due to aging, with a higher frequency observed in men over 50, as well as factors such as lifestyle, hormonal changes, and chronic conditions. Urethral stricture treatment devices are often used in managing urological issues such as BPH, where complications such as post-surgical effects or prolonged catheterization may cause urethral narrowing. This may require the use of dilators, stents, or urethrotomy tools to restore proper urinary function. For example, a report from the Royal Pharmaceutical Society in September 2023 stated that approximately 3 million individuals in the UK are affected by BPH, with 50% of men aged 60-70 years and 90% of men over 80 years experiencing the condition. Therefore, the increasing prevalence of BPH and neurogenic bladder is expected to contribute to the growth of the urethral stricture treatment devices market.
Leading companies in the urethral stricture treatment devices market are pursuing strategic partnerships to improve technology integration and broaden their market presence. A strategic partnership involves two or more organizations working together, sharing resources and expertise to achieve mutual objectives. For example, in April 2024, Laborie Medical Technologies Corp., a US-based company specializing in diagnostic and therapeutic medical technologies, formed a partnership with the NHS Specialized Services Device Programme (SSDP). This collaboration enabled the inclusion of Laborie’s Optilume Urethral Drug-Coated Balloon (DCB) in the program, ensuring reimbursement for NHS hospitals in England and improving patient access to the device. Optilume combines balloon dilation with anti-proliferative drug delivery, offering a solution to reduce the recurrence of urethral strictures. This innovative, minimally invasive technology provides an alternative to traditional surgery or repeated treatments, addressing a significant need within the field of urology.
In October 2023, Laborie Medical Technologies Corp., a US-based company specializing in diagnostic and therapeutic medical technologies, acquired Urotronic Inc. for an undisclosed sum. This acquisition allows Laborie to incorporate Urotronic’s Optilume drug-coated balloon technology into its range of interventional urology solutions. The technology is designed to treat conditions such as urethral strictures and benign prostatic hyperplasia (BPH). Urotronic Inc. is a US-based medical device company focused on developing urethral stricture treatment devices and other urological treatment technologies.
Major companies operating in the urethral stricture treatment devices market are Cardinal Health, Medtronic plc, Siemens Healthineers AG, Medline Industries LP., Becton Dickinson and Company, Stryker Corporation, Boston Scientific Corporation, B. Braun SE, Olympus Corporation, Coloplast Ltd, Teleflex Incorporated, Karl Storz SE & Co. KG, Cook Medical, ConvaTec Inc., Ambu A/S, Richard Wolf GmbH, Laborie Medical Technologies, Bactiguard AB, UROMED Kurt Drews KG, Pnn Medical A/S, Hydrumedical SA, Allium Ltd., Med pro Medical B.V., Urotronic Inc., Rocamed SAM, Zhejiang ChuangXiang Medical Technology Co. Ltd.
North America was the largest region in the urethral stricture treatment devices market in 2025. The regions covered in the urethral stricture treatment devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urethral stricture treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the urethral stricture treatment devices market by increasing costs of imported stents, catheters, and dilation devices. Balloon dilation and stent segments are most affected, particularly in regions reliant on global medical device supply chains. However, tariffs have encouraged regional manufacturing and innovation in cost-effective urology devices.
The urethral stricture treatment devices market research report is one of a series of new reports that provides urethral stricture treatment devices market statistics, including urethral stricture treatment devices industry global market size, regional shares, competitors with a urethral stricture treatment devices market share, detailed urethral stricture treatment devices market segments, market trends and opportunities, and any further data you may need to thrive in the urethral stricture treatment devices industry. This urethral stricture treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Urethral stricture treatment devices are medical tools designed to address urethral stricture, a condition where the urethra becomes narrowed, often causing urinary retention and difficulty with urination. These devices work to widen or bypass the constricted area of the urethra, restoring normal urine flow, and are used in both surgical and non-surgical treatment options.
The primary products in urethral stricture treatment devices include urethral dilators, urethral stents, urethral balloon dilation catheters, and urinary catheters. Urethral dilators are instruments used to gradually widen or stretch a narrowed urethra, facilitating easier urine flow. They are commonly used in procedures to treat urethral strictures by progressively increasing the diameter of the urethra. The strictures may be located in either the anterior or posterior sections, and the devices are typically used by end users such as hospitals, specialty clinics, and other healthcare facilities.
The urethral stricture treatment devices market consists of sales of laser urethrotomy devices, biodegradable stents, lubricants, urethral calibration sets, and bougies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The urethral stricture treatment devices market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growth in minimally invasive urology, demand for long-term stent solutions, advanced biomaterial adoption, outpatient procedure expansion, personalized urology devices. Major trends in the forecast period include minimally invasive stricture management, balloon dilation technologies, advanced urethral stents, improved catheter materials, outpatient urology procedures.
The growing incidence of benign prostatic hyperplasia (BPH) and neurogenic bladder is expected to drive the growth of the urethral stricture treatment devices market. BPH is a common condition among older men, characterized by an enlarged prostate that can obstruct urinary flow and heighten the risk of urethral strictures. The rise in BPH cases is largely due to aging, with a higher frequency observed in men over 50, as well as factors such as lifestyle, hormonal changes, and chronic conditions. Urethral stricture treatment devices are often used in managing urological issues such as BPH, where complications such as post-surgical effects or prolonged catheterization may cause urethral narrowing. This may require the use of dilators, stents, or urethrotomy tools to restore proper urinary function. For example, a report from the Royal Pharmaceutical Society in September 2023 stated that approximately 3 million individuals in the UK are affected by BPH, with 50% of men aged 60-70 years and 90% of men over 80 years experiencing the condition. Therefore, the increasing prevalence of BPH and neurogenic bladder is expected to contribute to the growth of the urethral stricture treatment devices market.
Leading companies in the urethral stricture treatment devices market are pursuing strategic partnerships to improve technology integration and broaden their market presence. A strategic partnership involves two or more organizations working together, sharing resources and expertise to achieve mutual objectives. For example, in April 2024, Laborie Medical Technologies Corp., a US-based company specializing in diagnostic and therapeutic medical technologies, formed a partnership with the NHS Specialized Services Device Programme (SSDP). This collaboration enabled the inclusion of Laborie’s Optilume Urethral Drug-Coated Balloon (DCB) in the program, ensuring reimbursement for NHS hospitals in England and improving patient access to the device. Optilume combines balloon dilation with anti-proliferative drug delivery, offering a solution to reduce the recurrence of urethral strictures. This innovative, minimally invasive technology provides an alternative to traditional surgery or repeated treatments, addressing a significant need within the field of urology.
In October 2023, Laborie Medical Technologies Corp., a US-based company specializing in diagnostic and therapeutic medical technologies, acquired Urotronic Inc. for an undisclosed sum. This acquisition allows Laborie to incorporate Urotronic’s Optilume drug-coated balloon technology into its range of interventional urology solutions. The technology is designed to treat conditions such as urethral strictures and benign prostatic hyperplasia (BPH). Urotronic Inc. is a US-based medical device company focused on developing urethral stricture treatment devices and other urological treatment technologies.
Major companies operating in the urethral stricture treatment devices market are Cardinal Health, Medtronic plc, Siemens Healthineers AG, Medline Industries LP., Becton Dickinson and Company, Stryker Corporation, Boston Scientific Corporation, B. Braun SE, Olympus Corporation, Coloplast Ltd, Teleflex Incorporated, Karl Storz SE & Co. KG, Cook Medical, ConvaTec Inc., Ambu A/S, Richard Wolf GmbH, Laborie Medical Technologies, Bactiguard AB, UROMED Kurt Drews KG, Pnn Medical A/S, Hydrumedical SA, Allium Ltd., Med pro Medical B.V., Urotronic Inc., Rocamed SAM, Zhejiang ChuangXiang Medical Technology Co. Ltd.
North America was the largest region in the urethral stricture treatment devices market in 2025. The regions covered in the urethral stricture treatment devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urethral stricture treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the urethral stricture treatment devices market by increasing costs of imported stents, catheters, and dilation devices. Balloon dilation and stent segments are most affected, particularly in regions reliant on global medical device supply chains. However, tariffs have encouraged regional manufacturing and innovation in cost-effective urology devices.
The urethral stricture treatment devices market research report is one of a series of new reports that provides urethral stricture treatment devices market statistics, including urethral stricture treatment devices industry global market size, regional shares, competitors with a urethral stricture treatment devices market share, detailed urethral stricture treatment devices market segments, market trends and opportunities, and any further data you may need to thrive in the urethral stricture treatment devices industry. This urethral stricture treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Urethral stricture treatment devices are medical tools designed to address urethral stricture, a condition where the urethra becomes narrowed, often causing urinary retention and difficulty with urination. These devices work to widen or bypass the constricted area of the urethra, restoring normal urine flow, and are used in both surgical and non-surgical treatment options.
The primary products in urethral stricture treatment devices include urethral dilators, urethral stents, urethral balloon dilation catheters, and urinary catheters. Urethral dilators are instruments used to gradually widen or stretch a narrowed urethra, facilitating easier urine flow. They are commonly used in procedures to treat urethral strictures by progressively increasing the diameter of the urethra. The strictures may be located in either the anterior or posterior sections, and the devices are typically used by end users such as hospitals, specialty clinics, and other healthcare facilities.
The urethral stricture treatment devices market consists of sales of laser urethrotomy devices, biodegradable stents, lubricants, urethral calibration sets, and bougies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Urethral Stricture Treatment Devices Market Characteristics
3. Urethral Stricture Treatment Devices Market Supply Chain Analysis
4. Global Urethral Stricture Treatment Devices Market Trends and Strategies
5. Urethral Stricture Treatment Devices Market Analysis of End Use Industries
7. Global Urethral Stricture Treatment Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Urethral Stricture Treatment Devices Total Addressable Market (TAM) Analysis for the Market
9. Urethral Stricture Treatment Devices Market Segmentation
10. Urethral Stricture Treatment Devices Market Regional and Country Analysis
11. Asia-Pacific Urethral Stricture Treatment Devices Market
12. China Urethral Stricture Treatment Devices Market
13. India Urethral Stricture Treatment Devices Market
14. Japan Urethral Stricture Treatment Devices Market
15. Australia Urethral Stricture Treatment Devices Market
16. Indonesia Urethral Stricture Treatment Devices Market
17. South Korea Urethral Stricture Treatment Devices Market
18. Taiwan Urethral Stricture Treatment Devices Market
19. South East Asia Urethral Stricture Treatment Devices Market
20. Western Europe Urethral Stricture Treatment Devices Market
21. UK Urethral Stricture Treatment Devices Market
22. Germany Urethral Stricture Treatment Devices Market
23. France Urethral Stricture Treatment Devices Market
24. Italy Urethral Stricture Treatment Devices Market
25. Spain Urethral Stricture Treatment Devices Market
26. Eastern Europe Urethral Stricture Treatment Devices Market
27. Russia Urethral Stricture Treatment Devices Market
28. North America Urethral Stricture Treatment Devices Market
29. USA Urethral Stricture Treatment Devices Market
30. Canada Urethral Stricture Treatment Devices Market
31. South America Urethral Stricture Treatment Devices Market
32. Brazil Urethral Stricture Treatment Devices Market
33. Middle East Urethral Stricture Treatment Devices Market
34. Africa Urethral Stricture Treatment Devices Market
36. Urethral Stricture Treatment Devices Market Competitive Landscape and Company Profiles
37. Urethral Stricture Treatment Devices Market Other Major and Innovative Companies
40. Urethral Stricture Treatment Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Urethral Stricture Treatment Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses urethral stricture treatment devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for urethral stricture treatment devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The urethral stricture treatment devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Urethral Dilators; Urethral Stents; Urethral Balloon Dilation Catheters; Urinary Catheters2) By Stricture Location: Anterior; Posterior
3) By End-User: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Urethral Dilators: Semi-Rigid Urethral Dilators; Flexible Urethral Dilators; Balloon Urethral Dilators; Graded Urethral Dilators2) By Urethral Stents: Self-Expanding Urethral Stents; Balloon-Expandable Urethral Stents; Metallic Urethral Stents; Silicone Urethral Stents
3) By Urethral Balloon Dilation Catheters: Single-Balloon Dilation Catheters; Double-Balloon Dilation Catheters; Coaxial Balloon Dilation Catheters; Hydrophilic-Coated Balloon Dilation Catheters
4) By Urinary Catheters: Foley Urinary Catheters; Intermittent Urinary Catheters; External Urinary Catheters; Supra-Pubic Urinary Catheters
Companies Mentioned: Cardinal Health; Medtronic plc; Siemens Healthineers AG; Medline Industries LP.; Becton Dickinson and Company; Stryker Corporation; Boston Scientific Corporation; B. Braun SE; Olympus Corporation; Coloplast Ltd; Teleflex Incorporated; Karl Storz SE & Co. KG; Cook Medical; ConvaTec Inc.; Ambu A/S; Richard Wolf GmbH; Laborie Medical Technologies; Bactiguard AB; UROMED Kurt Drews KG; Pnn Medical A/S; Hydrumedical SA; Allium Ltd.; Med pro Medical B.V.; Urotronic Inc.; Rocamed SAM; Zhejiang ChuangXiang Medical Technology Co. Ltd
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Urethral Stricture Treatment Devices market report include:- Cardinal Health
- Medtronic plc
- Siemens Healthineers AG
- Medline Industries LP.
- Becton Dickinson and Company
- Stryker Corporation
- Boston Scientific Corporation
- B. Braun SE
- Olympus Corporation
- Coloplast Ltd
- Teleflex Incorporated
- Karl Storz SE & Co. KG
- Cook Medical
- ConvaTec Inc.
- Ambu A/S
- Richard Wolf GmbH
- Laborie Medical Technologies
- Bactiguard AB
- UROMED Kurt Drews KG
- Pnn Medical A/S
- Hydrumedical SA
- Allium Ltd.
- Med pro Medical B.V.
- Urotronic Inc.
- Rocamed SAM
- Zhejiang ChuangXiang Medical Technology Co. Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.59 Billion |
| Forecasted Market Value ( USD | $ 2.14 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
